GlassScriptPhysician profile
Kenneth Chen Fan
NPI 1780032839
$41,319.18
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $254 · 2021: $485 · 2022: $4,494 · 2023: $7,987 · 2024: $7,320 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $4,199 · Honoraria: $1,390 · Travel and Lodging: $99.08 · Education: $31.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,802.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,233.53 |
| Food and Beverage | $4,199.06 |
| Honoraria | $1,390.00 |
| Travel and Lodging | $99.08 |
| Education | $31.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12,536.86 | 2021-2025 | Eylea Hd, Eylea |
| Eyepoint US, INC. | $5,548.50 | 2022-2024 | |
| Abbvie INC. | $4,612.20 | 2022-2025 | |
| Insmed, INC. | $4,408.33 | 2025 | Arikayce |
| Astellas Pharma US INC | $3,493.79 | 2023-2025 | Izervay |
| Ocular Therapeutix, INC. | $2,298.69 | 2024-2025 | Dextenza |
| Janssen Pharmaceuticals, INC | $1,815.00 | 2024 | |
| Alimera Sciences, INC. | $1,705.70 | 2021-2024 | Iluvien, Yutiq |
| Regeneron Pharmaceuticals, INC. | $1,254.69 | 2022-2023 | Eylea |
| Alcon Vision LLC | $783.84 | 2019-2022 | |
| Boehringer Ingelheim International Gmbh | $660.00 | 2024 | |
| Harrow Eye, LLC | $456.92 | 2024 | Iheezo |
| Apellis Pharmaceuticals, INC. | $417.46 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $285.81 | 2022-2025 | Vabysmo |
| Biogen, INC. | $185.03 | 2023-2024 | Byooviz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $137.61 | 2022 | |
| Ani Pharmaceuticals, INC. | $130.00 | 2025 | Yutiq |
| Oyster Point Pharma, INC. | $121.90 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $119.93 | 2019 | |
| Sun Pharmaceutical Industries INC. | $99.68 | 2025 | |
| Allergan, INC. | $91.87 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $86.17 | 2019 | |
| Dutch Ophthalmic, USA | $53.27 | 2021-2024 | Eva, Combined Machine, Tissueblue |
| Itamar Medical INC | $15.93 | 2023 | Watchpatone |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.